| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 74 | 2020 | 262 | 10.040 |
Why?
|
| Hyperthermia, Induced | 68 | 2020 | 246 | 9.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 47 | 2020 | 158 | 5.390 |
Why?
|
| Appendiceal Neoplasms | 29 | 2020 | 98 | 5.060 |
Why?
|
| Liver Neoplasms | 18 | 2018 | 159 | 4.780 |
Why?
|
| Colorectal Neoplasms | 23 | 2020 | 216 | 4.570 |
Why?
|
| Pancreatic Neoplasms | 12 | 2020 | 140 | 4.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2021 | 461 | 4.500 |
Why?
|
| Hepatectomy | 20 | 2018 | 64 | 4.070 |
Why?
|
| Gallbladder Neoplasms | 22 | 2021 | 36 | 3.480 |
Why?
|
| Bile Duct Neoplasms | 21 | 2019 | 36 | 3.400 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2020 | 370 | 3.390 |
Why?
|
| Combined Modality Therapy | 64 | 2020 | 565 | 3.200 |
Why?
|
| Adenocarcinoma | 19 | 2019 | 311 | 3.070 |
Why?
|
| Survival Rate | 72 | 2021 | 885 | 2.720 |
Why?
|
| Chemotherapy, Adjuvant | 26 | 2021 | 192 | 2.280 |
Why?
|
| Prognosis | 59 | 2021 | 1505 | 2.200 |
Why?
|
| Pancreaticoduodenectomy | 9 | 2020 | 24 | 2.110 |
Why?
|
| Middle Aged | 128 | 2021 | 11868 | 2.030 |
Why?
|
| Retrospective Studies | 73 | 2021 | 3523 | 1.990 |
Why?
|
| Humans | 189 | 2021 | 32025 | 1.950 |
Why?
|
| Aged | 114 | 2021 | 10340 | 1.900 |
Why?
|
| Carcinoma | 17 | 2017 | 92 | 1.890 |
Why?
|
| Female | 143 | 2021 | 19954 | 1.820 |
Why?
|
| Surgical Wound Infection | 5 | 2019 | 86 | 1.740 |
Why?
|
| Antineoplastic Agents | 21 | 2020 | 607 | 1.710 |
Why?
|
| Male | 130 | 2021 | 19196 | 1.680 |
Why?
|
| Follow-Up Studies | 49 | 2021 | 2280 | 1.660 |
Why?
|
| Neoplasm Staging | 48 | 2020 | 456 | 1.650 |
Why?
|
| Negative-Pressure Wound Therapy | 3 | 2019 | 36 | 1.610 |
Why?
|
| Pancreatectomy | 5 | 2019 | 32 | 1.530 |
Why?
|
| Mitomycin | 17 | 2020 | 52 | 1.510 |
Why?
|
| Treatment Outcome | 52 | 2020 | 3317 | 1.460 |
Why?
|
| Postoperative Complications | 17 | 2020 | 785 | 1.400 |
Why?
|
| Colonic Neoplasms | 12 | 2016 | 71 | 1.290 |
Why?
|
| Biliary Tract Neoplasms | 5 | 2018 | 10 | 1.290 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 19 | 1.280 |
Why?
|
| Adult | 74 | 2020 | 9367 | 1.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 22 | 2019 | 70 | 1.090 |
Why?
|
| Cholangiocarcinoma | 7 | 2019 | 14 | 1.050 |
Why?
|
| Vascular Surgical Procedures | 4 | 2017 | 90 | 1.040 |
Why?
|
| Laparoscopy | 4 | 2019 | 174 | 1.030 |
Why?
|
| Adenocarcinoma, Mucinous | 7 | 2020 | 29 | 1.020 |
Why?
|
| Aged, 80 and over | 46 | 2019 | 4000 | 0.990 |
Why?
|
| Lymphatic Metastasis | 31 | 2018 | 170 | 0.970 |
Why?
|
| Melanoma | 9 | 2019 | 164 | 0.930 |
Why?
|
| Prospective Studies | 36 | 2020 | 2283 | 0.910 |
Why?
|
| Medical Oncology | 3 | 2019 | 84 | 0.890 |
Why?
|
| Skin Neoplasms | 10 | 2019 | 214 | 0.890 |
Why?
|
| Lymph Nodes | 11 | 2020 | 106 | 0.880 |
Why?
|
| Neoplasms | 9 | 2020 | 692 | 0.840 |
Why?
|
| Biliary Tract Surgical Procedures | 3 | 2017 | 8 | 0.820 |
Why?
|
| Antibiotics, Antineoplastic | 7 | 2007 | 74 | 0.810 |
Why?
|
| Pancreatic Fistula | 1 | 2020 | 5 | 0.740 |
Why?
|
| Laparotomy | 4 | 2017 | 30 | 0.730 |
Why?
|
| Infusions, Parenteral | 17 | 2016 | 66 | 0.720 |
Why?
|
| Mesothelioma | 6 | 2019 | 39 | 0.710 |
Why?
|
| Case Management | 1 | 2019 | 5 | 0.700 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2019 | 13 | 0.670 |
Why?
|
| Bile Ducts | 2 | 2018 | 21 | 0.670 |
Why?
|
| Vascular Fistula | 1 | 2019 | 4 | 0.660 |
Why?
|
| Seroma | 1 | 2019 | 5 | 0.660 |
Why?
|
| Electroporation | 1 | 2019 | 14 | 0.660 |
Why?
|
| Intestinal Fistula | 1 | 2019 | 9 | 0.660 |
Why?
|
| Risk Assessment | 11 | 2017 | 1435 | 0.660 |
Why?
|
| Ablation Techniques | 1 | 2019 | 26 | 0.650 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 757 | 0.650 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 407 | 0.640 |
Why?
|
| Vascular Neoplasms | 2 | 2010 | 13 | 0.630 |
Why?
|
| Leiomyosarcoma | 2 | 2010 | 9 | 0.630 |
Why?
|
| United States | 22 | 2020 | 3938 | 0.620 |
Why?
|
| Vena Cava, Inferior | 2 | 2010 | 32 | 0.620 |
Why?
|
| Quality of Life | 11 | 2020 | 933 | 0.610 |
Why?
|
| Anesthesia, Conduction | 1 | 2018 | 25 | 0.600 |
Why?
|
| Travel | 1 | 2017 | 15 | 0.600 |
Why?
|
| Disease-Free Survival | 14 | 2018 | 319 | 0.600 |
Why?
|
| Neoplasm Invasiveness | 10 | 2017 | 194 | 0.600 |
Why?
|
| Digestive System Neoplasms | 1 | 2017 | 4 | 0.580 |
Why?
|
| Blood Vessels | 3 | 2017 | 49 | 0.570 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2017 | 20 | 0.570 |
Why?
|
| Young Adult | 18 | 2020 | 2615 | 0.550 |
Why?
|
| Analgesia, Epidural | 1 | 2017 | 51 | 0.550 |
Why?
|
| Breast Neoplasms | 12 | 2013 | 761 | 0.540 |
Why?
|
| Choledochal Cyst | 1 | 2015 | 6 | 0.510 |
Why?
|
| Abdominal Neoplasms | 4 | 2014 | 15 | 0.510 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 179 | 0.490 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 36 | 0.480 |
Why?
|
| Time Factors | 16 | 2018 | 2152 | 0.480 |
Why?
|
| Thalidomide | 1 | 2014 | 31 | 0.480 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 687 | 0.460 |
Why?
|
| Peritoneum | 6 | 2020 | 33 | 0.460 |
Why?
|
| Databases, Factual | 12 | 2020 | 355 | 0.450 |
Why?
|
| Blood Transfusion | 4 | 2019 | 74 | 0.440 |
Why?
|
| Cholecystectomy | 6 | 2020 | 22 | 0.440 |
Why?
|
| Neoplasm Metastasis | 8 | 2016 | 221 | 0.440 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 111 | 0.440 |
Why?
|
| Survival Analysis | 10 | 2016 | 488 | 0.430 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2017 | 33 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 918 | 0.400 |
Why?
|
| Risk Factors | 14 | 2018 | 3869 | 0.400 |
Why?
|
| Stomach Neoplasms | 5 | 2016 | 84 | 0.380 |
Why?
|
| Portal Vein | 2 | 2017 | 28 | 0.370 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2010 | 50 | 0.350 |
Why?
|
| Length of Stay | 7 | 2018 | 318 | 0.340 |
Why?
|
| Adolescent | 14 | 2017 | 3526 | 0.340 |
Why?
|
| Neoplasm, Residual | 8 | 2018 | 25 | 0.340 |
Why?
|
| Catheter Ablation | 4 | 2005 | 67 | 0.330 |
Why?
|
| Predictive Value of Tests | 13 | 2019 | 878 | 0.330 |
Why?
|
| Reoperation | 7 | 2017 | 227 | 0.330 |
Why?
|
| Patient Selection | 5 | 2021 | 277 | 0.310 |
Why?
|
| Common Bile Duct | 3 | 2020 | 8 | 0.310 |
Why?
|
| Biopsy | 1 | 2009 | 260 | 0.310 |
Why?
|
| Incidence | 5 | 2018 | 1200 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 5 | 2016 | 67 | 0.310 |
Why?
|
| Preoperative Care | 4 | 2017 | 115 | 0.300 |
Why?
|
| Microwaves | 1 | 2007 | 8 | 0.290 |
Why?
|
| Electrocoagulation | 1 | 2007 | 12 | 0.290 |
Why?
|
| Pseudomyxoma Peritonei | 3 | 2013 | 12 | 0.280 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2016 | 21 | 0.280 |
Why?
|
| Gene Expression | 1 | 2008 | 335 | 0.280 |
Why?
|
| Organoplatinum Compounds | 5 | 2016 | 47 | 0.270 |
Why?
|
| Morbidity | 7 | 2017 | 99 | 0.260 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 23 | 0.250 |
Why?
|
| Logistic Models | 3 | 2017 | 781 | 0.250 |
Why?
|
| Abdominal Wall | 1 | 2004 | 22 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 77 | 0.240 |
Why?
|
| Lymph Node Excision | 9 | 2020 | 90 | 0.240 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 323 | 0.230 |
Why?
|
| Hepatic Veins | 1 | 2003 | 4 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 94 | 0.220 |
Why?
|
| Sarcoma | 2 | 2014 | 71 | 0.220 |
Why?
|
| Coloring Agents | 5 | 2009 | 29 | 0.210 |
Why?
|
| Cohort Studies | 9 | 2020 | 1831 | 0.210 |
Why?
|
| Registries | 2 | 2017 | 298 | 0.210 |
Why?
|
| Cryosurgery | 1 | 2002 | 20 | 0.210 |
Why?
|
| Positron-Emission Tomography | 3 | 2010 | 163 | 0.210 |
Why?
|
| Liver | 2 | 2014 | 483 | 0.200 |
Why?
|
| Radiopharmaceuticals | 5 | 2010 | 93 | 0.200 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 300 | 0.200 |
Why?
|
| Incidental Findings | 5 | 2021 | 25 | 0.190 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2018 | 9 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 72 | 0.190 |
Why?
|
| Rosaniline Dyes | 7 | 2009 | 18 | 0.190 |
Why?
|
| CA-19-9 Antigen | 2 | 2017 | 6 | 0.180 |
Why?
|
| Drainage | 2 | 2017 | 72 | 0.180 |
Why?
|
| Risk | 2 | 2020 | 319 | 0.180 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 271 | 0.180 |
Why?
|
| Ileal Neoplasms | 2 | 2013 | 4 | 0.180 |
Why?
|
| Jejunal Neoplasms | 2 | 2013 | 7 | 0.180 |
Why?
|
| Frail Elderly | 2 | 2017 | 69 | 0.180 |
Why?
|
| Depression | 4 | 2020 | 443 | 0.180 |
Why?
|
| Models, Statistical | 2 | 2020 | 173 | 0.170 |
Why?
|
| Carcinoma, Lobular | 3 | 2011 | 12 | 0.170 |
Why?
|
| Pancreatic Diseases | 1 | 2019 | 18 | 0.160 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 45 | 0.160 |
Why?
|
| Pain Measurement | 2 | 2017 | 351 | 0.160 |
Why?
|
| Caregivers | 1 | 2020 | 113 | 0.160 |
Why?
|
| Neutrophils | 2 | 2016 | 112 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 391 | 0.150 |
Why?
|
| Intensive Care Units | 2 | 2015 | 110 | 0.150 |
Why?
|
| Hepatic Artery | 1 | 2017 | 15 | 0.150 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 298 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2019 | 218 | 0.150 |
Why?
|
| Jaundice, Obstructive | 1 | 2017 | 3 | 0.150 |
Why?
|
| Diaphragm | 2 | 2014 | 40 | 0.150 |
Why?
|
| Endoscopy | 1 | 2017 | 57 | 0.150 |
Why?
|
| Income | 1 | 2017 | 61 | 0.150 |
Why?
|
| Sensitivity and Specificity | 10 | 2011 | 594 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2017 | 22 | 0.150 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 1 | 0.140 |
Why?
|
| Survivors | 1 | 2018 | 159 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2018 | 179 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 261 | 0.140 |
Why?
|
| Mastectomy, Segmental | 2 | 2010 | 27 | 0.140 |
Why?
|
| Mastectomy | 4 | 2013 | 65 | 0.140 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2016 | 7 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2017 | 25 | 0.140 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2017 | 20 | 0.140 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 9 | 0.140 |
Why?
|
| Splenectomy | 2 | 2014 | 21 | 0.140 |
Why?
|
| Disease Progression | 3 | 2014 | 594 | 0.140 |
Why?
|
| Intraoperative Period | 7 | 2018 | 42 | 0.140 |
Why?
|
| Health Status | 5 | 2019 | 399 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 63 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 242 | 0.140 |
Why?
|
| Nomograms | 1 | 2016 | 32 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2016 | 57 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 128 | 0.140 |
Why?
|
| Hospital Mortality | 2 | 2014 | 198 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 30 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 159 | 0.130 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 8 | 0.130 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.130 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 144 | 0.130 |
Why?
|
| Palliative Care | 1 | 2016 | 52 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 61 | 0.130 |
Why?
|
| Shock, Septic | 1 | 2015 | 26 | 0.130 |
Why?
|
| Rectal Neoplasms | 2 | 2013 | 18 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2015 | 47 | 0.130 |
Why?
|
| Patient Admission | 1 | 2015 | 60 | 0.130 |
Why?
|
| Bandages | 2 | 2013 | 33 | 0.120 |
Why?
|
| Intraoperative Care | 6 | 2015 | 48 | 0.120 |
Why?
|
| Ileal Diseases | 1 | 2014 | 3 | 0.120 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.120 |
Why?
|
| Vomiting | 1 | 2014 | 24 | 0.120 |
Why?
|
| Hernia, Abdominal | 1 | 2014 | 10 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2014 | 12 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 40 | 0.120 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 12 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2014 | 82 | 0.120 |
Why?
|
| Nausea | 1 | 2014 | 53 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2014 | 34 | 0.120 |
Why?
|
| Appendix | 1 | 2014 | 4 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 39 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 900 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2015 | 474 | 0.120 |
Why?
|
| Cytological Techniques | 2 | 2011 | 17 | 0.120 |
Why?
|
| Ascites | 1 | 2013 | 16 | 0.110 |
Why?
|
| Urinary Tract | 1 | 2013 | 22 | 0.110 |
Why?
|
| Urologic Diseases | 1 | 2013 | 27 | 0.110 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 6 | 0.110 |
Why?
|
| Wound Healing | 2 | 2013 | 185 | 0.110 |
Why?
|
| Consensus | 1 | 2013 | 85 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 49 | 0.110 |
Why?
|
| Cisplatin | 4 | 2014 | 77 | 0.110 |
Why?
|
| Taxoids | 1 | 2013 | 59 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2013 | 62 | 0.100 |
Why?
|
| Child | 7 | 2014 | 2441 | 0.100 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2009 | 5 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 161 | 0.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2009 | 21 | 0.100 |
Why?
|
| Feasibility Studies | 4 | 2016 | 292 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 411 | 0.100 |
Why?
|
| Tumor Burden | 3 | 2016 | 60 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 11 | 0.090 |
Why?
|
| Decision Making | 1 | 2012 | 194 | 0.090 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2009 | 9 | 0.080 |
Why?
|
| Mammaplasty | 1 | 2009 | 28 | 0.080 |
Why?
|
| Frozen Sections | 4 | 2018 | 18 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 23 | 0.080 |
Why?
|
| Carboplatin | 3 | 2013 | 48 | 0.080 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1169 | 0.080 |
Why?
|
| Perioperative Care | 2 | 2019 | 59 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1324 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2008 | 18 | 0.080 |
Why?
|
| Complement System Proteins | 1 | 2008 | 9 | 0.080 |
Why?
|
| ROC Curve | 2 | 2018 | 167 | 0.080 |
Why?
|
| Perfusion | 2 | 2020 | 73 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 57 | 0.070 |
Why?
|
| Nevus | 2 | 2004 | 15 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 27 | 0.070 |
Why?
|
| Lymphatic Vessels | 2 | 2017 | 5 | 0.070 |
Why?
|
| Cell Death | 1 | 2007 | 77 | 0.070 |
Why?
|
| Necrosis | 1 | 2007 | 53 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 11 | 0.070 |
Why?
|
| Mental Health | 2 | 2019 | 115 | 0.070 |
Why?
|
| Equipment Design | 1 | 2007 | 172 | 0.070 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2006 | 3 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 95 | 0.070 |
Why?
|
| Hemoperitoneum | 1 | 2006 | 4 | 0.070 |
Why?
|
| Animals | 3 | 2008 | 7466 | 0.070 |
Why?
|
| Telomerase | 1 | 2006 | 22 | 0.070 |
Why?
|
| Activities of Daily Living | 4 | 2011 | 259 | 0.070 |
Why?
|
| Probability | 2 | 2016 | 158 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 55 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 160 | 0.070 |
Why?
|
| Colectomy | 3 | 2014 | 25 | 0.070 |
Why?
|
| Endosonography | 1 | 2006 | 56 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 130 | 0.060 |
Why?
|
| African Americans | 1 | 2013 | 1428 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1179 | 0.060 |
Why?
|
| Quality of Health Care | 2 | 2020 | 147 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 61 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 70 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 52 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2016 | 544 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 532 | 0.060 |
Why?
|
| Skin, Artificial | 1 | 2004 | 33 | 0.060 |
Why?
|
| North Carolina | 3 | 2015 | 1516 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 518 | 0.060 |
Why?
|
| Keratins | 3 | 2010 | 39 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 765 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2015 | 124 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2015 | 128 | 0.060 |
Why?
|
| Massage | 1 | 2003 | 12 | 0.060 |
Why?
|
| Breast | 1 | 2003 | 61 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 2014 | 45 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 59 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 409 | 0.050 |
Why?
|
| Swine | 1 | 2003 | 215 | 0.050 |
Why?
|
| Cytodiagnosis | 3 | 2011 | 16 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2003 | 76 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 131 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2004 | 232 | 0.050 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2014 | 9 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1530 | 0.040 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 12 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 126 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 70 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 94 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 80 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2016 | 923 | 0.040 |
Why?
|
| Appendectomy | 1 | 2018 | 15 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 28 | 0.040 |
Why?
|
| Data Collection | 1 | 2018 | 180 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 261 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 35 | 0.040 |
Why?
|
| Netherlands | 1 | 2017 | 22 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 91 | 0.040 |
Why?
|
| Malpractice | 1 | 2017 | 21 | 0.040 |
Why?
|
| Bilirubin | 1 | 2017 | 25 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 108 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 58 | 0.040 |
Why?
|
| Fluorescent Dyes | 2 | 2007 | 48 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 24 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 2016 | 12 | 0.040 |
Why?
|
| Leucovorin | 1 | 2016 | 25 | 0.040 |
Why?
|
| Camptothecin | 1 | 2016 | 52 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 34 | 0.030 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 45 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 82 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 125 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 56 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2016 | 82 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 83 | 0.030 |
Why?
|
| Peripheral Nerves | 1 | 2016 | 62 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 42 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 140 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 80 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 148 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 185 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 507 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 240 | 0.030 |
Why?
|
| Mammography | 2 | 2005 | 42 | 0.030 |
Why?
|
| Omentum | 1 | 2014 | 26 | 0.030 |
Why?
|
| Pneumonia | 1 | 2014 | 67 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 73 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 57 | 0.030 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 93 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 149 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 15 | 0.030 |
Why?
|
| Axilla | 2 | 2003 | 18 | 0.030 |
Why?
|
| International Agencies | 1 | 2012 | 10 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 897 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2012 | 39 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 21 | 0.020 |
Why?
|
| Sleep | 1 | 2012 | 92 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 286 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 67 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 60 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 734 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 639 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 40 | 0.020 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2009 | 69 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 19 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 61 | 0.020 |
Why?
|
| Neck | 1 | 2007 | 27 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 197 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 7 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2006 | 20 | 0.020 |
Why?
|
| Rupture | 1 | 2006 | 34 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 53 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1194 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 197 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 203 | 0.020 |
Why?
|
| Atmospheric Pressure | 1 | 2004 | 10 | 0.010 |
Why?
|
| Vacuum | 1 | 2004 | 22 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 2004 | 21 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2004 | 18 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 2004 | 42 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 38 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 294 | 0.010 |
Why?
|
| Face | 1 | 2003 | 29 | 0.010 |
Why?
|
| Cell Biology | 1 | 2002 | 2 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 225 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 33 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 39 | 0.010 |
Why?
|
| Cryopreservation | 1 | 2002 | 57 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 56 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 496 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 210 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1269 | 0.010 |
Why?
|